EWING, NJ--(Marketwire - February 13, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or “The Company”), a late-stage drug development company, announced today that positive results for orBec® (oral beclomethasone dipropionate or oral BDP) in preventing serious lung injury in patients with gastrointestinal Graft-versus-Host disease (GI GVHD), will be presented this afternoon by Jason W. Chien, MD of the Fred Hutchinson Cancer Research Center (FHCRC) at the annual Tandem Bone Marrow Transplant Meeting of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry in San Diego. The presentation is entitled “Preservation of pulmonary diffusing capacity with oral beclomethasone dipropionate: Results from two randomized, placebo-controlled trials in allogeneic graft recipients,” published in Biology of Blood and Marrow Transplantation (Volume 14, Number 2, Supplement 2). DOR is also the Sponsor of the GVHD Working Committee at the conference on Thursday, February 14.
